Vir Biotechnology, Inc.

As of June 30, 2026, Vir Biotechnology, Inc. carries a market capitalization of 1.30B, placing it among publicly traded companies globally. Its enterprise value stands at 941.55M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Vir Biotechnology, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Vir Biotechnology, Inc. has 169.19M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 4.65, and the price-to-book ratio stands at 1.63.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.85 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 941.55M versus a market cap of 1.30B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Vir Biotechnology, Inc. maintains a current ratio of 6.04, meaning it holds 6.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Vir Biotechnology, Inc. posted a negative return on equity (ROE) of -26.08, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -20.91, reflecting losses generated across the asset base. The company generates approximately 647,953.54 in revenue per employee across its workforce of 377.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Vir Biotechnology, Inc. recorded 306,975.40 in income tax expense. The company reported a pretax loss of -203.01M and -203.31M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Over the twelve months ended June 30, 2026, Vir Biotechnology, Inc. generated 244.44M in revenue and converted that into -203.31M in net income, yielding earnings per share of -1.37. EBITDA reached -217.05M, while operating income came in at -226.34M.

As of June 30, 2026, Vir Biotechnology, Inc. holds 430.35M in cash and equivalents against 75.35M in total debt, resulting in a net debt position of -225.17M. Total book value stands at 793.69M, with working capital of 386.77M providing operational flexibility.

Vir Biotechnology, Inc. produced -163.59M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -878,111.21 in capital expenditures, free cash flow totaled -164.47M - equivalent to -1.11 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -92.60 and net profit margin of -83.18 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -14.44: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -15.08, meaning Vir Biotechnology, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Vir Biotechnology, Inc. has an Altman Z-Score of 2.64, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.